Biogen Idec Inc (BIIB): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.4%. By the end of trading, Biogen Idec rose $6.66 (2.0%) to $335.11 on average volume. Throughout the day, 1,302,371 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,355,400 shares. The stock ranged in a price between $323.31-$335.88 after having opened the day at $330.33 as compared to the previous trading day's close of $328.45. Other companies within the Drugs industry that increased today were: Ultragenyx Pharmaceutical ( RARE), up 17.1%, Raptor Pharmaceutical ( RPTP), up 14.9%, China Biologic Products ( CBPO), up 11.9% and Catalyst Pharmaceutical Partners ( CPRX), up 11.7%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $79.2 billion and is part of the health care sector. Shares are up 19.8% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Onconova Therapeutics ( ONTX), down 36.6%, Aoxing Pharmaceutical Company ( AXN), down 11.5%, Cardiome Pharma Corporation ( CRME), down 9.7% and Prana Biotechnology ( PRAN), down 7.9%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%